 This is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppressive therapy with Prograf capsules tacrolimus, Astellas Pharma US, Inc., Deerfield, IL twice daily to maintenance immunotherapy with LCP TacroTM tablets tacrolimus, LifeCycle Pharma AS, Hoersholm, Denmark once daily for the prevention of acute allograft rejection in stable adult kidney transplant patients. Patients on a stable dose of Prograf will be randomly assigned to be converted from Prograf twice daily to LCP TacroTM once daily or to remain on maintenance therapy with Prograf twice daily. Patients entering the study will be treated with assigned study drug and followed for one year for patient survival and the incidence of graft rejection or graft loss. 